1. The Latest Lipid Guidelines:

3. Goals

4. Evolution of Lipid Guidelines

5. Evolution of Lipid Guidelines (cont)

6. Evolution of Lipid Guidelines (cont)

7. Lowering LDL-C Reduces Risk for Major CV Events

8. IMPROVE-IT: Benefit With Ezetimibe

9. FOURIER: Profound LDL-C Reductions

10. FOURIER: CV Outcomes

11. Evolution of Lipid Guidelines (cont)

12. FOURIER: LDL Cholesterol In patients with baseline LDL-C≤70 mg/dL

13. FOURIER: Clinical Outcomes In patients with baseline LDL-C<70 mg/dL

14. FOURIER Analysis: Time-Weighted Median LDL-Cholesterol Concentrations

15. FOURIER Analysis: CV Death, MI, Stroke

16. LDL-C: Target, Goals, and Thresholds for Nonstatin Therapy

17. Evolution of Lipid Guidelines (cont)

18. Non-HDL-C and ApoB Considered Important Thresholds for ASCVD (ODYSSEY)

19. 2017 ACC EXPERT CONSENSUS DECISION PATHWAY

20. Examples of High-, Moderate-, and Low-Intensity Statin Therapy

21. Algorithm for Stepwise Approach in Treatment of Heterozygous FH and Clinical ASCVD with PCSK9 Inhibitors

22. FOURIER: Safety Events By Achieved LDL-C At 4 Weeks After Randomization

23. FOURIER: Safety Events By Achieved LDL-C At 4 Weeks After Randomization (cont)

24. FOURIER: New-Onset Diabetes

25. FOURIER: Glycemic Parameters

26. Considerations Prior to Starting PCSK9 Inhibitors

27. Take Home Points

28. Abbreviations

29. Abbreviations (cont)

30. Abbreviations (cont)

31. Abbreviations (cont)